Warning Letter — Lexia LLC: Center for Drug Evaluation and Research (CDER)
The FDA issued a Warning Letter to Lexia LLC following concerns identified by the Center for Drug Evaluation and Research (CDER).
The directive affects Lexia LLC and its associated regulatory, quality, and clinical departments involved in CDER-regulated activities.
The issuance of a Warning Letter by CDER indicates that previously identified compliance issues or inspectional observations remained unresolved to the agency's satisfaction. This suggests a breakdown in the firm's quality or regulatory oversight, potentially leading to increased regulatory scrutiny, delays in product approvals, or further enforcement actions if the cited deficiencies are not remediated promptly. The source provides limited detail on the specific nature of the violations.
Regulatory and Quality teams should review all recent FDA correspondence and inspectional findings to ensure comprehensive and timely responses are submitted. Firms should audit their internal systems for managing CDER-related regulatory obligations to prevent the escalation of unresolved compliance issues into formal Warning Letters.
FDA issued a Warning Letter to Lexia LLC. Subject: Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lexia-llc-722251-04072026
Open in openFDA / FDA.gov